iRhythm Technologies (NASDAQ:IRTC) Announces Earnings Results, Beats Estimates By $0.62 EPS

iRhythm Technologies (NASDAQ:IRTC) released its earnings results on Thursday. The company reported $0.58 earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.62, FiscalAI reports. The company had revenue of $224.17 million during the quarter, compared to the consensus estimate of $219.30 million. iRhythm Technologies had a negative return on equity of 10.26% and a negative net margin of 3.53%.iRhythm Technologies’s revenue was up 20.1% compared to the same quarter last year. During the same period in the previous year, the company posted ($0.32) EPS.

Here are the key takeaways from iRhythm Technologies’ conference call:

• Q2 revenue rose 20.1% to $224.2 million, marking the seventh consecutive quarter of more than 20% growth. Adjusted EBITDA margin reached 19.3%, free cash flow was a record $37.5 million, and adjusted net income improved to $19.3 million.
• iRhythm raised its 2026 outlook to $880 million-$890 million in revenue and a 13%-14% adjusted EBITDA margin, citing sustained volume growth, operating efficiencies, and disciplined expense management.
• The pending VitalConnect acquisition is intended to broaden iRhythm’s MCT offering and add capabilities in inpatient monitoring, hospital-to-home care, remote patient monitoring, and multi-vital sensing. Management expects revenue contribution beginning in 2027 and believes the combined company can reach its previously stated 15% adjusted EBITDA margin target in 2027.
• FDA clearance of iRhythm’s third-generation algorithm could reduce technician review time by up to 50% and generate approximately $100 million in cumulative cost savings over five years after its planned first-half 2027 launch.
• Key execution and regulatory risks remain, including the pending FDA warning-letter resolution, HSR review and integration of VitalConnect, and continued uncertainty around the timing of Zio MCT clearance. The company also agreed to pay $50 million to settle litigation with Baxter, while a June cybersecurity incident involved data exfiltration despite no reported material operational or financial impact.

iRhythm Technologies Price Performance

Shares of NASDAQ IRTC opened at $128.12 on Friday. The company has a debt-to-equity ratio of 4.03, a quick ratio of 4.98 and a current ratio of 5.17. iRhythm Technologies has a fifty-two week low of $100.85 and a fifty-two week high of $212.00. The stock’s 50-day simple moving average is $114.76 and its 200-day simple moving average is $124.55. The firm has a market capitalization of $4.21 billion, a PE ratio of -148.98 and a beta of 1.30.

Insiders Place Their Bets

In related news, Director Abhijit Y. Talwalkar acquired 5,312 shares of the firm’s stock in a transaction on Monday, May 11th. The stock was bought at an average price of $10.71 per share, for a total transaction of $56,891.52. Following the completion of the purchase, the director directly owned 25,611 shares of the company’s stock, valued at approximately $274,293.81. The trade was a 26.17% increase in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.98% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the business. US Bancorp DE boosted its holdings in iRhythm Technologies by 7.8% in the third quarter. US Bancorp DE now owns 1,042 shares of the company’s stock valued at $179,000 after purchasing an additional 75 shares during the last quarter. State of Wyoming increased its holdings in iRhythm Technologies by 16.0% during the 4th quarter. State of Wyoming now owns 616 shares of the company’s stock worth $109,000 after purchasing an additional 85 shares during the last quarter. Alliancebernstein L.P. raised its position in shares of iRhythm Technologies by 0.3% in the 3rd quarter. Alliancebernstein L.P. now owns 37,489 shares of the company’s stock valued at $6,448,000 after purchasing an additional 95 shares in the last quarter. California State Teachers Retirement System raised its position in shares of iRhythm Technologies by 0.3% in the 2nd quarter. California State Teachers Retirement System now owns 28,917 shares of the company’s stock valued at $4,452,000 after purchasing an additional 99 shares in the last quarter. Finally, Vanguard Personalized Indexing Management LLC boosted its stake in shares of iRhythm Technologies by 4.3% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 2,472 shares of the company’s stock valued at $439,000 after buying an additional 102 shares during the last quarter.

iRhythm Technologies News Roundup

Here are the key news stories impacting iRhythm Technologies this week:

• Positive Sentiment: Q2 results exceeded expectations. iRhythm reported adjusted earnings of $0.58 per share, versus analyst estimates calling for a loss of approximately $0.01–$0.04, while revenue increased 20.1% year over year to $224.17 million, above the $219.30 million consensus. iRhythm Q2 earnings report
• Positive Sentiment: VitalConnect acquisition expands the company’s addressable market. iRhythm agreed to acquire VitalConnect for $287.5 million, adding technology for cardiac monitoring across ambulatory, inpatient and hospital-to-home settings. Management expects the transaction to close by year-end, subject to customary conditions. iRhythm to buy VitalConnect
• Positive Sentiment: Management provided a solid 2026 outlook. iRhythm forecast revenue of $880 million to $890 million, broadly in line with the $881.3 million consensus, and is targeting a 13%–14% adjusted EBITDA margin. The guidance signals continued revenue growth alongside improving profitability. iRhythm 2026 outlook
• Neutral Sentiment: Investors will monitor integration and execution risks. The VitalConnect deal could broaden iRhythm’s product portfolio, but the purchase price, closing process and integration requirements may affect near-term cash flow and margins.
• Neutral Sentiment: Legal uncertainty appears to be moving toward resolution. A federal court approved notice of a proposed class-action settlement involving purchasers of iRhythm common stock. The available announcement did not provide the settlement’s financial impact, limiting its immediate valuation significance. iRhythm proposed class action settlement

Wall Street Analyst Weigh In

A number of brokerages recently weighed in on IRTC. Needham & Company LLC restated a “buy” rating and issued a $192.00 price objective on shares of iRhythm Technologies in a report on Friday. Truist Financial dropped their price target on shares of iRhythm Technologies from $174.00 to $160.00 and set a “buy” rating for the company in a research note on Thursday, July 16th. JPMorgan Chase & Co. reduced their price objective on iRhythm Technologies from $215.00 to $175.00 and set an “overweight” rating on the stock in a research note on Friday, May 1st. Wells Fargo & Company lowered their target price on iRhythm Technologies from $200.00 to $180.00 and set an “overweight” rating for the company in a research note on Friday, May 1st. Finally, Wall Street Zen raised iRhythm Technologies from a “hold” rating to a “buy” rating in a research report on Saturday, July 18th. Two investment analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $180.21.

iRhythm Technologies Company Profile

iRhythm Technologies, Inc is a medical technology company that develops and commercializes wearable cardiac monitoring devices and associated data analytics services. Founded in 2006 and headquartered in San Francisco, California, the company’s flagship product is the Zio® patch, a discreet, single-use, continuous ECG recorder designed to monitor heart rhythms for up to 14 days. iRhythm’s digital diagnostics platform combines biosensor technology with proprietary algorithms to detect arrhythmias and streamline data interpretation for physicians.

The Zio service is prescribed by cardiologists and other healthcare providers to aid in the diagnosis of atrial fibrillation, bradycardia, tachycardia and other rhythm disorders.